8,695
Views
88
CrossRef citations to date
0
Altmetric
Coronaviruses

Homologous or heterologous booster of inactivated vaccine reduces SARS-CoV-2 Omicron variant escape from neutralizing antibodies

, , , , , , , , , , , & ORCID Icon show all
Pages 477-481 | Received 27 Dec 2021, Accepted 12 Jan 2022, Published online: 04 Feb 2022

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (8)

Camilo C. Roa$suffix/text()$suffix/text(), Mari Rose A. de Los Reyes, Eric Plennevaux, Igor Smolenov, Branda Hu, Faith Gao, Hannalyn Ilagan, Donna Ambrosino, George Siber, Ralf Clemens & Htay Htay Han. (2024) SCB-2019 protein vaccine as heterologous booster of neutralizing activity against SARS-CoV-2 Omicron variants after immunization with other COVID-19 vaccines. Human Vaccines & Immunotherapeutics 20:1.
Read now
Rea Bingula, Hélène Chabrolles, Benjamin Bonnet, Christine Archimbaud, Amélie Brebion, Justine Cosme, Amandine Ollier, Frédéric Dutheil, Maud Junda, Audrey Mirand, Christel Regagnon, Magali Vidal, Cécile Henquell & Bertrand Evrard. (2023) Increase over time of antibody levels 3 months after a booster dose as an indication of better protection against Omicron infection. Emerging Microbes & Infections 12:1.
Read now
Hongyu Wang, Quanlin Xue, Haocheng Zhang, Guanmin Yuan, Xun Wang, Kai Sheng, Chen Li, Jianpeng Cai, Yuhan Sun, Jingjing Zhao, Jiahuan Lu, Shuyu Fang, Yongfeng Yang, Yeting Zhang, Ying Huang, Jiancui Wang, Jonathan H. Xu, Melissa X. Jiang, Xinyu Wang, Lei Shen, Yuanyuan Liu, Qihui Liu, Qiran Zhang, Sen Wang, Pengfei Wang, Chao Qiu, Jingwen Ai & Wenhong Zhang. (2023) Neutralization against Omicron subvariants after BA.5/BF.7 breakthrough infection weakened as virus evolution and aging despite repeated prototype-based vaccination1. Emerging Microbes & Infections 12:2.
Read now
Sue Ann Costa Clemens, Natalie Marchevsky, Sarah Kelly, Sally Felle, Ahmed Eldawi, Rupetha Rajasingam, Rawan Mahmud, Teresa Lambe, Merryn Voysey, Isabela Gonzalez, Eveline Pipolo Milan, Maria Cleonice Justino, Sagida Bibi, Parvinder Aley, Ralf Clemens & Andrew J. Pollard. (2023) Immunogenicity, safety and reactogenicity of heterologous (third dose) booster vaccination with a full or fractional dose of two different COVID-19 vaccines: A phase 4, single-blind, randomized controlled trial in adults. Human Vaccines & Immunotherapeutics 19:2.
Read now
Dong Wei, Yingying Chen, Xiaoqi Yu, Yang-dian Lai, Wenxin Xu, Ping Ji, Zhitao Yang, Erzhen Chen, Xinxin Zhang & Ying Wang. (2022) Comparable antigen-specific T cell responses in vaccinees with diverse humoral immune responses after the primary and booster BBIBP-CorV vaccination. Emerging Microbes & Infections 11:1, pages 2474-2484.
Read now
Xiaoxu Zhang, Bixia Hong, Peng Wei, Pengfei Pei, Haifeng Xu, Long Chen, Yigang Tong, Jialin Chen, Shi-Zhong Luo, Huahao Fan & Chengzhi He. (2022) Pathogen-host adhesion between SARS-CoV-2 spike proteins from different variants and human ACE2 studied at single-molecule and single-cell levels. Emerging Microbes & Infections 11:1, pages 2658-2669.
Read now
Tian Yao, Xiaohong Zhang, Shengcai Mu, Yana Guo, Xiuyang Xu, Junfeng Huo, Zhiyun Wei, Ling Liu, Xiaoqing Li, Hong Li, Rongqin Xing, Yongliang Feng, Jing Chen, Lizhong Feng & Suping Wang. (2022) Immune persistence induced by two-dose BBIBP-CorV vaccine with different intervals, and immunogenicity and safety of a homologous booster dose in high-risk occupational population. Expert Review of Vaccines 21:12, pages 1883-1893.
Read now
Aizhen Huang, Yanting Lu, Jingjing Ji, Yankun Yao, Shiping Guan, Zirong Chen & Lu Yu. (2022) The effect of COVID-19 vaccination on epileptic seizures in patients with epilepsy: A clinical observation in China. Human Vaccines & Immunotherapeutics 18:6.
Read now

Articles from other publishers (80)

Congrui Zhu, Shengmei Pang, Jiaqi Liu & Qiangde Duan. (2024) Current Progress, Challenges and Prospects in the Development of COVID-19 Vaccines. Drugs.
Crossref
Ranjan K. Mohapatra, Venkataramana Kandi, Abhay M Gaidhane, Quazi Syed Zahiruddin, Sarvesh Rustagi, Prakasini Satapathy, Snehasish Mishra & Lawrence Sena Tuglo. (2024) Global domination of the recently VoI-classified 'JN.1′ outcompeting other variants – Comparing the vaccines’ efficacy. Clinical Infection in Practice 22, pages 100358.
Crossref
Jowita Frączkiewicz, Katarzyna Pawińska-Wąsikowska, Katarzyna Szymbor, Walentyna Balwierz, Szymon Skoczeń, Krzysztof Czyżewski, Sylwia Kołtan, Jan Styczyński, Anna Małecka, Ninela Irga-Jaworska, Joanna Trelińska, Wojciech Młynarski, Olga Zając-Spychała, Agnieszka Sobkowiak-Sobierajska, Katarzyna Derwich, Wioletta Bal, Radosław Chaber, Agnieszka Książek, Tomasz Szczepański, Joanna Zawitkowska, Katarzyna Drabko, Agnieszka Chodała-Grzywacz, Grażyna Karolczyk, Christopher Kobierzycki & Krzysztof Kałwak. (2024) Pre-Exposure Prophylaxis and Treatment with Tixagevimab/Cilgavimab for COVID-19 among Immunocompromised Pediatric Patients. Journal of Clinical Medicine 13:7, pages 2029.
Crossref
Xiaoyu Zhao, Tianyi Qiu, Xiner Huang, Qiyu Mao, Yajie Wang, Rui Qiao, Jiayan Li, Tiantian Mao, Yuan Wang, Yewei Cun, Caicui Wang, Cuiting Luo, Chaemin Yoon, Xun Wang, Chen Li, Yuchen Cui, Chaoyue Zhao, Minghui Li, Yanjia Chen, Guonan Cai, Wenye Geng, Zixin Hu, Jinglei Cao, Wenhong Zhang, Zhiwei Cao, Hin Chu, Lei Sun & Pengfei Wang. (2024) Potent and broadly neutralizing antibodies against sarbecoviruses induced by sequential COVID-19 vaccination. Cell Discovery 10:1.
Crossref
Panke Qu, Kai Xu, Julia N. Faraone, Negin Goodarzi, Yi-Min Zheng, Claire Carlin, Joseph S. Bednash, Jeffrey C. Horowitz, Rama K. Mallampalli, Linda J. Saif, Eugene M. Oltz, Daniel Jones, Richard J. Gumina & Shan-Lu Liu. (2024) Immune evasion, infectivity, and fusogenicity of SARS-CoV-2 BA.2.86 and FLip variants. Cell 187:3, pages 585-595.e6.
Crossref
Na RenZhihong WangSikang Gao. (2024) Immunogenicity Persistence of a Third-Dose Homologous BBIBP-CorV/CoronaVac Boosting Vaccination: A Prospective Open-Label Study. Viral Immunology 37:1, pages 16-23.
Crossref
Denggao Peng, Liuqing Yang, Cheng Jin, Jiaqi Feng, Mengli Cao & Yingxia Liu. (2024) Effect of second booster vaccination on clinical outcomes of Omicron-variant breakthrough infection: A propensity score matching cohort study. Heliyon 10:1, pages e23344.
Crossref
Xun Wang, Shujun Jiang, Wentai Ma, Xiangnan Li, Kaifeng Wei, Faren Xie, Chaoyue Zhao, Xiaoyu Zhao, Shidi Wang, Chen Li, Rui Qiao, Yuchen Cui, Yanjia Chen, Jiayan Li, Guonan Cai, Changyi Liu, Jizhen Yu, Jixi Li, Zixin Hu, Wenhong Zhang, Shibo Jiang, Mingkun Li, Yanliang Zhang & Pengfei Wang. (2024) Enhanced neutralization of SARS-CoV-2 variant BA.2.86 and XBB sub-lineages by a tetravalent COVID-19 vaccine booster. Cell Host & Microbe 32:1, pages 25-34.e5.
Crossref
Ziteng Liang, Jincheng Tong, Ziqi Sun, Shuo Liu, Jiajing Wu, Xi Wu, Tao Li, Yuanling Yu, Li Zhang, Chenyan Zhao, Qiong Lu, Jianhui Nie, Weijin Huang & Youchun Wang. (2024) Rational prediction of immunogenicity clustering through cross‐reactivity analysis of thirteen SARS‐CoV‐2 variants. Journal of Medical Virology 96:1.
Crossref
Hudachuan Jiang, Pengfei Jin, Xiling Guo, Jiahong Zhu, Xue Wang, Peng Wan, Jingxuan Wan, Jingxian Liu, Jingxin Li & Fengcai Zhu. (2023) The 6-Month Antibody Durability of Heterologous Convidecia Plus CoronaVac and Homologous CoronaVac Immunizations in People Aged 18–59 Years and over 60 Years Based on Two Randomized Controlled Trials in China. Vaccines 11:12, pages 1815.
Crossref
Yan Wu, Jian Shi, Xiaoxue He, Jia Lu, Xiao Gao, Xuerui Zhu, Xinlan Chen, Man Zhang, Lijuan Fang, Jing Zhang, Zhiming Yuan, Gengfu Xiao, Pengfei Zhou & Xiaoyan Pan. (2023) Protection of the receptor binding domain (RBD) dimer against SARS-CoV-2 and its variants. Journal of Virology 97:11.
Crossref
Svetoslav N. Slavov, Alex R. J. Lima, Gabriela Ribeiro, Loyze P. O. de Lima, Claudia R. dos S. Barros, Elaine C. Marqueze, Antonio J. Martins, Maiara Martininghi, Melissa Palmieri, Luiz A. V. Caldeira, Fabiana E. V. da Silva, Giselle Cacherik, Aline L. Nicolodelli, Simone Kashima, Marta Giovanetti, Luiz Carlos Junior Alcantara, Sandra C. Sampaio & Maria C. Elias. (2023) Epidemiological and Genomic Analysis of Asymptomatic SARS-CoV-2 Infections during the Delta and Omicron Epidemic Waves in São Paulo City, Brazil. Viruses 15:11, pages 2210.
Crossref
Taoyuan Li, Shaorong WuJiaxiong TanZhengyi HuangLijun LiWenzhi LuoYayun WuJun LyuXujing Liang. (2023) Epidemiologic Characteristics of SARS-CoV-2 Omicron BA.5.1.3 Variant and the Protection Provided By Inactivated Vaccination. Viral Immunology 36:8, pages 544-549.
Crossref
Julia N. Faraone, Panke Qu, Yi-Min Zheng, Claire Carlin, Daniel Jones, Ashish R. Panchal, Linda J. Saif, Eugene M. Oltz, Richard J. Gumina & Shan-Lu Liu. (2023) Continued evasion of neutralizing antibody response by Omicron XBB.1.16. Cell Reports 42:10, pages 113193.
Crossref
Ting Zeng, Kailu Wang, Zihao Guo, Shengzhi Sun, Ziyu Zhai, Yaoqin Lu, Zhidong Teng, Daihai He, Kai Wang, Maozai Tian & Shi Zhao. (2023) Distinguishing the Vaccine Effectiveness of Inactivated BBIBP-CorV Vaccine Booster Against the Susceptibility, Infectiousness, and Transmission of Omicron Stains: A Retrospective Cohort Study in Urumqi, China. Infectious Diseases and Therapy 12:10, pages 2405-2416.
Crossref
Xun Wang, Minghui Li, Panpan Lu, Chen Li, Chaoyue Zhao, Xiaoyu Zhao, Rui Qiao, Yuchen Cui, Yanjia Chen, Jiayan Li, Guonan Cai & Pengfei Wang. (2023) In Vitro Antibody-Dependent Enhancement of SARS-CoV-2 Infection Could Be Abolished by Adding Human IgG. Pathogens 12:9, pages 1108.
Crossref
Maoshun Liu, Jie Zhang, Lei Li, Jinmin Tian, Mengjie Yang, Bingli Shang, Xin Wang, Min Li, Hongmei Li, Can Yue, Sijia Yao, Ying Lin, Yuanyuan Guo, Kexin Zong, Danni Zhang, Yingze Zhao, Kun Cai, Shaobo Dong, Shengping Xu, Jianbo Zhan, George F. Gao & William J. Liu. (2023) Inactivated vaccine fueled adaptive immune responses to Omicron in 2‐year COVID‐19 convalescents. Journal of Medical Virology 95:8.
Crossref
Yuhao Lin, Qiqi Sun, Bao Zhang, Wei Zhao & Chenguang Shen. (2023) The regulation of lncRNAs and miRNAs in SARS-CoV-2 infection. Frontiers in Cell and Developmental Biology 11.
Crossref
Xun Wang, Shuai Jiang, Shujun Jiang, Xiangnan Li, Jingwen Ai, Ke Lin, Shiyun Lv, Shixuan Zhang, Minghui Li, Jixi Li, Lili Dai, Zixin Hu, Wenhong Zhang, Yanliang Zhang & Pengfei Wang. (2023) Neutralization of SARS-CoV-2 BQ.1.1, CH.1.1, and XBB.1.5 by breakthrough infection sera from previous and recent waves in China. Cell Discovery 9:1.
Crossref
James A. Williams, Marco BiancucciLaura Lessen, Sai Tian, Ankita BalsarafLynn ChenChelsy Chesterman, Giulietta Maruggi, Sarah VandepaerYing HuangCorey P. Mallett, Ann-Muriel Steff, Matthew James Bottomley, Enrico Malito, Newton Wahome & Wayne D. Harshbarger. (2023) Structural and computational design of a SARS-CoV-2 spike antigen with improved expression and immunogenicity. Science Advances 9:23.
Crossref
Yufen Zheng, Juan Pan, Minya Jin, Jing Wang, Tao-Hsin Tung, Shiyong Chen, Xiaojie Bi, Kai Zhou, Mengyuan Chen, Donglian Wang, Jun Li, Bo Shen & Lingjun Ying. (2023) Efficacy of the neutralizing antibodies after the booster dose on SARS-CoV-2 Omicron variant and a two-year longitudinal antibody study on Wild Type convalescents. International Immunopharmacology 119, pages 110151.
Crossref
Uttpal Anand, Tarun Pal, Alessandra Zanoletti, Suresh Sundaramurthy, Sunita Varjani, Anushka Upamali Rajapaksha, Damià Barceló & Elza Bontempi. (2023) The spread of the omicron variant: Identification of knowledge gaps, virus diffusion modelling, and future research needs. Environmental Research 225, pages 115612.
Crossref
Panke Qu, Julia N. Faraone, John P. Evans, Yi-Min Zheng, Claire Carlin, Mirela Anghelina, Patrick Stevens, Soledad Fernandez, Daniel Jones, Ashish R. Panchal, Linda J. Saif, Eugene M. Oltz, Baoshan Zhang, Tongqing Zhou, Kai Xu, Richard J. Gumina & Shan-Lu Liu. (2023) Enhanced evasion of neutralizing antibody response by Omicron XBB.1.5, CH.1.1, and CA.3.1 variants. Cell Reports 42:5, pages 112443.
Crossref
Anna Yu. Popova, Vyacheslav S. Smirnov, Svetlana A. Egorova, Artavazd V. Vanyan, Angelika M. Milichkina, Nune G. Bakunts, Irina V. Drozd, Romella A. Abovyan, Valeriy A. Ivanov, Gayane G. Melik-Andreasyan, Edward Smith Ramsay, Gennady O. Palozyan, Tatyana V. Arbuzova, Ara Sh. Keshishyan, Ouna B. Zhimbayeva, Olga A. Petrova, Alexandra V. Gubanova, Alexandra P. Razumovskaya & Areg A. Totolian. (2023) SARS-CoV-2 collective immunity among the population of the Republic of Armenia. Russian Journal of Infection and Immunity 13:1, pages 75-90.
Crossref
Hongming Huang & Jia Liu. (2023) Role of inactivated SARS-CoV-2 vaccine induced T cell responses in ameliorating COVID-19 severity. Virologica Sinica 38:2, pages 324-326.
Crossref
Lidong Wang, Michelle Møhlenberg, Pengfei Wang & Hao Zhou. (2023) Immune evasion of neutralizing antibodies by SARS-CoV-2 Omicron. Cytokine & Growth Factor Reviews 70, pages 13-25.
Crossref
Rashmi Rana, Ravi Kant, Tanya Kumra, Sneha Gupta, Devinder Singh Rana & Nirmal Kumar Ganguly. (2023) An update on SARS-CoV-2 immunization and future directions. Frontiers in Pharmacology 14.
Crossref
Yanjia Chen, Xiaoyu Zhao, Hao Zhou, Huanzhang Zhu, Shibo Jiang & Pengfei Wang. (2022) Broadly neutralizing antibodies to SARS-CoV-2 and other human coronaviruses. Nature Reviews Immunology 23:3, pages 189-199.
Crossref
Shiheng Wu, Xiaolin Wang, Mingyang Feng, Xiaoman Liu, Xinxing Fan, Xiangui Ran, Baogui Wang & Hui Wang. (2023) Safety and immunogenicity of inactivated COVID-19 vaccine CoronaVac and the RBD-dimer–based COVID-19 vaccine ZF2001 in chronic hepatitis B patients. Frontiers in Medicine 10.
Crossref
Mong-Lien Wang, Yang Lin, Ju-Fen Hou, Yi-Ping Yang, Yueh Chien, Yi-Chen Sun, Kung-Hao Liang, De-Ming Yang, Tai-Jay Chang, Cheng-Hsien Wu, Shou-Yen Kao & Kai-Feng Hung. (2022) The Omicron variant wave: Where are we now and what are the prospects?. Journal of the Chinese Medical Association 86:2, pages 135-137.
Crossref
Shanhong Mao, Shiyou Li, Yuxin Zhang, Luoxin Long, Junfeng Peng, Yuanyan Cao, Jessica Z. Mao, Xin Qi, Qi Xin, Guoliang San, Jing Ding, Jun Jiang, Xuejiao Bai, Qianting Wang, Pengfei Xu, Huan Xia, Lijun Lu, Liangzhi Xie, Desheng Kong, Shuangli Zhu & Wenbo Xu. (2023) A highly efficient needle-free-injection delivery system for mRNA-LNP vaccination against SARS-CoV-2. Nano Today 48, pages 101730.
Crossref
Anna Offersgaard, Carlos Rene Duarte Hernandez, Shan Feng, Pavel Marichal-Gallardo, Kenn Holmbeck, Anne Finne Pihl, Carlota Fernandez-Antunez, Garazi Peña Alzua, Katrine Top Hartmann, Long V. Pham, Yuyong Zhou, Karen Anbro Gammeltoft, Ulrik Fahnøe, Uffe Vest Schneider, Gabriel Kristian Pedersen, Henrik Elvang Jensen, Jan Pravsgaard Christensen, Santseharay Ramirez, Jens Bukh & Judith Margarete Gottwein. (2023) An inactivated SARS-CoV-2 vaccine induced cross-neutralizing persisting antibodies and protected against challenge in small animals. iScience 26:2, pages 105949.
Crossref
Enagnon Kazali Alidjinou, Julie Demaret, Bénédicte Corroyer-Simovic, Fanny Vuotto, Sophie Miczek, Julien Labreuche, Anne Goffard, Jacques Trauet, Daniela Lupau, Arnaud Dendooven, Dominique Huvent-Grelle, Juliette Podvin, Daniel Dreuil, Karine Faure, Dominique Deplanque, Laurence Bocket, Alain Duhamel, Annie Sobaszek, Didier Hober, Michael Hisbergues, Francois Puisieux, Brigitte Autran, Yazdan Yazdanpanah, Myriam Labalette & Guillaume Lefèvre. (2023) Serum neutralization of SARS coronavirus 2 Omicron sublineages BA.1 and BA.2 and cellular immune responses 3 months after booster vaccination. Clinical Microbiology and Infection 29:2, pages 258.e1-258.e4.
Crossref
Xun Wang, Xing He, Shujun Jiang, Zhangfan Fu, Shuai Jiang, Xiaoyu Zhao, Chaoyue Zhao, Yaning Li, Dianfan Li, Wenhong Zhang, Jingwen Ai, Yanliang Zhang, Chenqi Xu & Pengfei Wang. (2023) Limited enhancement of antibody and B‐cell responses to prototype booster vaccination following SARS‐CoV‐2 Delta breakthrough infection. Journal of Medical Virology 95:2.
Crossref
Yu-Feng Mao, Lin Gao, Yuan-Yuan Li & Fu-Sheng Wang. (2023) Safety and Efficacy of SARS-CoV-2 Vaccination in Patients With Chronic Liver Disease. Infectious Diseases & Immunity Publish Ahead of Print.
Crossref
Caroline Atyeo, Lydia L. Shook, Nadege Nziza, Elizabeth A. Deriso, Cordelia Muir, Arantxa Medina Baez, Rosiane S. Lima, Stepan Demidkin, Sara Brigida, Rose M. De Guzman, Madeleine D. Burns, Alejandro B. Balazs, Alessio Fasano, Lael M. Yonker, Kathryn J. Gray, Galit Alter & Andrea G. Edlow. (2023) COVID-19 booster dose induces robust antibody response in pregnant, lactating, and nonpregnant women. American Journal of Obstetrics and Gynecology 228:1, pages 68.e1-68.e12.
Crossref
Dan‐yun Lai, Jun‐biao Xue, Ping He, He‐wei Jiang, Yang Li, Ming‐liang Ma, Wei Hong, Jun‐ping Yu, Hong‐ping Wei & Sheng‐ce Tao. (2022) Longitudinal neutralization activities on authentic Omicron variant provided by three doses of BBIBP‐CorV vaccination during one year. PROTEOMICS 23:2.
Crossref
Julien Favresse, Constant Gillot, Jean‐Louis Bayart, Clara David, Germain Simon, Loris Wauthier, Mélanie Closset, Jean‐Michel Dogné & Jonathan Douxfils. (2022) Vaccine‐induced binding and neutralizing antibodies against Omicron 6 months after a homologous BNT162b2 booster. Journal of Medical Virology 95:1.
Crossref
Chao Wang, Bei Liu, Sihui Zhang, Ninghua Huang, Tianshuo Zhao, Qing‐Bin Lu & Fuqiang Cui. (2022) Differences in incidence and fatality of COVID‐19 by SARS‐CoV‐2 Omicron variant versus Delta variant in relation to vaccine coverage: A world‐wide review. Journal of Medical Virology 95:1.
Crossref
Xue-Jun Wang, Lin Yao, Hong-Yun Zhang, Ka-Li Zhu, Jing Zhao, Bing-Dong Zhan, Yi-Ke Li, Xue-Juan He, Cong Huang, Zhuang-Ye Wang, Ming-Dong Jiang, Peng Yang, Yang Yang, Guo-Lin Wang, Sheng-Qi Wang, Er-Hei Dai, Hui-Xia Gao & Mai-Juan Ma. (2022) Neutralization sensitivity, fusogenicity, and infectivity of Omicron subvariants. Genome Medicine 14:1.
Crossref
Junxiang Wang, Kaiyi Li, Xinyue Mei, Jinpeng Cao, Jiaying Zhong, Peiyu Huang, Qi Luo, Guichang Li, Rui Wei, Nanshan Zhong, Zhuxiang Zhao & Zhongfang Wang. (2022) SARS-CoV-2 vaccination-infection pattern imprints and diversifies T cell differentiation and neutralizing response against Omicron subvariants. Cell Discovery 8:1.
Crossref
Yuqi Zhu, Xinyi Yang, Jingna Xun, Jun Liu, Qing Wen, Yixiao Lin, Xiaoting Shen, Jun Chen, Songhua Yuan, Xiaying Zhao, Jing Wang, Hanyu Pan, Jinlong Yang, Zhiming Liang, Yue Liang, Qinru Lin, Huitong Liang, Min Li, Jianping Liu, Yinzhong Shen, Xiaoyan Zhang, Pengfei Wang, Daru Lu, Chunhua Yin, Jianqing Xu, Shibo Jiang, Hongzhou Lu & Huanzhang Zhu. (2022) Neutralization of five SARS-CoV-2 variants of concern by convalescent and BBIBP-CorV vaccinee serum. Virologica Sinica 37:6, pages 831-841.
Crossref
Yuemiao Zhang, Xupu Ma, Guanghong Yan, Ying Wu, Yanli Chen, Zumi Zhou, Na Wan, Wei Su, Feng-Wei Liu, Mu-Xian Dai, Mei Yang, Chunmei Li, Xuanjing Yu, Liang Zhang, Zhongfang Wang, Tai-Cheng Zhou, Dingyun You, Jia Wei & Zijie Zhang. (2022) Immunogenicity, durability, and safety of an mRNA and three platform-based COVID-19 vaccines as a third dose following two doses of CoronaVac in China: A randomised, double-blinded, placebo-controlled, phase 2 trial. eClinicalMedicine 54, pages 101680.
Crossref
Lili Li, Yangyang Wei, Han Yang, Junyu Yan, Xin Li, Ziqian Li, Yuxiu Zhao, Hongyang Liang & Hui Wang. (2022) Advances in Next-Generation Coronavirus Vaccines in Response to Future Virus Evolution. Vaccines 10:12, pages 2035.
Crossref
Ioannis Sitaras, Henning Jacobsen, Melissa M. Higdon, William E. Dowling, Naor Bar-Zeev & Maria Deloria Knoll. (2022) Systematic review of primary and booster COVID-19 sera neutralizing ability against SARS-CoV-2 omicron variant. npj Vaccines 7:1.
Crossref
Vivek Chavda, Rajashri Bezbaruah, Kangkan Deka, Lawandashisha Nongrang & Tutumoni Kalita. (2022) The Delta and Omicron Variants of SARS-CoV-2: What We Know So Far. Vaccines 10:11, pages 1926.
Crossref
Jie Zhang, Yishan Du, Pengfei Zhou, Jinru Ding, Shuai Xia, Qian Wang, Feiyang Chen, Mu Zhou, Xuemei Zhang, Weifeng Wang, Hongyan Wu, Lu Lu & Shaoting Zhang. (2022) Predicting unseen antibodies’ neutralizability via adaptive graph neural networks. Nature Machine Intelligence 4:11, pages 964-976.
Crossref
Chiranjib Chakraborty, Manojit Bhattacharya, Ashish Ranjan Sharma, Kuldeep Dhama & Sang-Soo Lee. (2022) The rapid emergence of multiple sublineages of Omicron (B.1.1.529) variant: Dynamic profiling via molecular phylogenetics and mutational landscape studies. Journal of Infection and Public Health 15:11, pages 1234-1258.
Crossref
Xun Wang, Xiaoyu Zhao, Yuchen Cui, Rui Qiao, Minghui Li, Yanjia Chen, Lulu Yang, Shibo Jiang & Pengfei Wang. (2022) Neutralization of distinct Omicron sublineages by longitudinal vaccination sera. Journal of Medical Virology 94:11, pages 5090-5092.
Crossref
Jiefeng Zhao, Jinfeng Zhu, Chao Huang, Xiaojian Zhu, Zhengming Zhu, Qinrong Wu & Rongfa Yuan. (2022) Uncovering the information immunology journals transmitted for COVID-19: A bibliometric and visualization analysis. Frontiers in Immunology 13.
Crossref
Juan Li, Hui Xie, Weixin Chen, Meng Chen, Shuang Bai, Wei Zhao, Tao Zhou, Pei Gao, Lichi Zhang, Quanyi Wang, Xinghuo Pang, Chun Huang & Jiang Wu. (2022) Immune Persistence against SARS-CoV-2 after Primary and Booster Immunization in Humans: A Large-Scale Prospective Cohort Study. Vaccines 10:10, pages 1677.
Crossref
Manuela Tamburro, Giancarlo Ripabelli, Antonio D’Amico, Roberta De Dona, Mariagrazia Iafigliola, Albino Parente, Nicandro Samprati, Arturo Santagata, Carmen Adesso, Anna Natale, Michela Anna Di Palma, Fabio Cannizzaro & Michela Lucia Sammarco. (2022) A Cross-Sectional Study of Untoward Reactions Following Homologous and Heterologous COVID-19 Booster Immunizations in Recipients Seventeen Years of Age and Older. Journal of Community Health 47:5, pages 814-821.
Crossref
Hao Zhou, Michelle Møhlenberg, Jigarji C. Thakor, Hardeep Singh Tuli, Pengfei Wang, Yehuda G. Assaraf, Kuldeep Dhama & Shibo Jiang. (2022) Sensitivity to Vaccines, Therapeutic Antibodies, and Viral Entry Inhibitors and Advances To Counter the SARS-CoV-2 Omicron Variant. Clinical Microbiology Reviews 35:3.
Crossref
Yousra Kherabi, Odile Launay & Liem Binh Luong Nguyen. (2022) COVID-19 Vaccines against Omicron Variant: Real-World Data on Effectiveness. Viruses 14:10, pages 2086.
Crossref
Lu Zhang, Hongquan Chen, Su Yang, Yang Zhao, Xiaoyun Shen, Xiaowen He, Haohui Ye, Deqin Wang, Jiazhou Lou, Yinshan Wang & Shengjun Wu. (2022) The impact of CoronaVac on the neutralization breadth and magnitude of the antibody response to SARS-CoV-2 viruses. Frontiers in Immunology 13.
Crossref
Gentil Arthur Bentes, Natália Maria Lanzarini, Juliana Rodrigues Guimarães, Marcos Bryan Heinemann, Eduardo de Mello Volotão, Alexandre dos Santos da Silva, Luiz Guilherme Dias Heneine, Jaqueline Mendes de Oliveira & Marcelo Alves Pinto. (2022) Production and Evaluation of Chicken Egg Yolk Immunoglobulin (IgY) against Human and Simian Rotaviruses. Viruses 14:9, pages 1995.
Crossref
Zichun Wei, Jiarui He, Conghui Wang, Jiaqi Bao, Taiyang Leng & Fei Chen. (2022) The importance of booster vaccination in the context of Omicron wave. Frontiers in Immunology 13.
Crossref
Li-Jun Duan, Wen-Guo Jiang, Zhuang-Ye Wang, Lin Yao, Ka-Li Zhu, Qing-Chuan Meng, Bao-Shan Wang, Li-Bo Li, Guo-Lin Wang & Mai-Juan Ma. (2022) Neutralizing immunity against SARS-CoV-2 Omicron BA.1 by infection and vaccination. iScience 25:9, pages 104886.
Crossref
Ailan Xu, Bixia Hong, Fuxing Lou, Shuqi Wang, Wenye Li, Amna Shafqat, Xiaoping An, Yunwei Zhao, Lihua Song, Yigang Tong & Huahao Fan. (2022) Sub‐lineages of the SARS‐CoV‐2 Omicron variants: Characteristics and prevention. MedComm 3:3.
Crossref
Kaiming Tao, Philip L. Tzou, Sergei L. Kosakovsky Pond, John P. A. Ioannidis & Robert W. Shafer. (2022) Susceptibility of SARS-CoV-2 Omicron Variants to Therapeutic Monoclonal Antibodies: Systematic Review and Meta-analysis. Microbiology Spectrum 10:4.
Crossref
Wei Qin, Xiaqing Zhang, Yao Wang, Fan Pan, Kai Cheng, Fangfang Huang, Jian Song & Hong Su. (2022) The acceptance to heterologous booster vaccination of COVID-19 vaccine among HCWs and targeted population: A cross-sectional study in central China. Frontiers in Public Health 10.
Crossref
Jingwen Ai, Xun Wang, Xinyi He, Xiaoyu Zhao, Yi Zhang, Yuchao Jiang, Minghui Li, Yuchen Cui, Yanjia Chen, Rui Qiao, Lin Li, Lulu Yang, Yi Li, Zixin Hu, Wenhong Zhang & Pengfei Wang. (2022) Antibody evasion of SARS-CoV-2 Omicron BA.1, BA.1.1, BA.2, and BA.3 sub-lineages. Cell Host & Microbe 30:8, pages 1077-1083.e4.
Crossref
John P. Evans, Cong Zeng, Panke Qu, Julia Faraone, Yi-Min Zheng, Claire Carlin, Joseph S. Bednash, Tongqing Zhou, Gerard Lozanski, Rama Mallampalli, Linda J. Saif, Eugene M. Oltz, Peter J. Mohler, Kai Xu, Richard J. Gumina & Shan-Lu Liu. (2022) Neutralization of SARS-CoV-2 Omicron sub-lineages BA.1, BA.1.1, and BA.2. Cell Host & Microbe 30:8, pages 1093-1102.e3.
Crossref
Yu Cao, Xiaoli Wang, Siqi Li, Yuan Dong, Yonghong Liu, Jing Li, Yanqing Zhao & Yingmei Feng. (2022) A third high dose of inactivated COVID-19 vaccine induces higher neutralizing antibodies in humans against the Delta and Omicron variants: a Randomized, Double-Blinded Clinical Trial. Science China Life Sciences 65:8, pages 1677-1679.
Crossref
Bing Zhou, Shuo Song, Huimin Guo, Xinrong Zhou, Qing Fan, Weilong Liu, Lin Cheng, Xiangyang Ge, Bin Ju & Zheng Zhang. (2022) A fourth dose of Omicron RBD vaccine enhances broad neutralization against SARS‐CoV‐2 variants including BA.1 and BA.2 in vaccinated mice. Journal of Medical Virology 94:8, pages 3992-3997.
Crossref
Dorota Zarębska-Michaluk, Chenlin Hu, Michał Brzdęk, Robert Flisiak & Piotr Rzymski. (2022) COVID-19 Vaccine Booster Strategies for Omicron SARS-CoV-2 Variant: Effectiveness and Future Prospects. Vaccines 10:8, pages 1223.
Crossref
Shuai Xia, Lijue Wang, Yun Zhu, Lu Lu & Shibo Jiang. (2022) Origin, virological features, immune evasion and intervention of SARS-CoV-2 Omicron sublineages. Signal Transduction and Targeted Therapy 7:1.
Crossref
Chenyuan Qin, Wenxin Yan, Liyuan Tao, Min Liu & Jue Liu. (2022) The Association between Risk Perception and Hesitancy toward the Booster Dose of COVID-19 Vaccine among People Aged 60 Years and Older in China. Vaccines 10:7, pages 1112.
Crossref
Eloy E Ordaya, Elena Beam, Joseph D Yao, Raymund R Razonable & Paschalis Vergidis. (2022) Characterization of Early-Onset Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Immunocompromised Patients Who Received Tixagevimab-Cilgavimab Prophylaxis. Open Forum Infectious Diseases 9:7.
Crossref
Santenna Chenchula, Padmavathi Karunakaran, Sushil Sharma & Madhavrao Chavan. (2022) Current evidence on efficacy of COVID‐19 booster dose vaccination against the Omicron variant: A systematic review. Journal of Medical Virology 94:7, pages 2969-2976.
Crossref
Irene González-Domínguez, Jose Luis Martínez, Stefan Slamanig, Nicholas Lemus, Yonghong Liu, Tsoi Ying Lai, Juan Manuel Carreño, Gagandeep Singh, Gagandeep Singh, Michael Schotsaert, Ignacio Mena, Stephen McCroskery, Lynda Coughlan, Florian Krammer, Adolfo García-Sastre, Peter Palese & Weina Sun. (2022) Trivalent NDV-HXP-S Vaccine Protects against Phylogenetically Distant SARS-CoV-2 Variants of Concern in Mice. Microbiology Spectrum 10:3.
Crossref
Cong Sun, Chu Xie, Guo-Long Bu, Lan-Yi Zhong & Mu-Sheng Zeng. (2022) Molecular characteristics, immune evasion, and impact of SARS-CoV-2 variants. Signal Transduction and Targeted Therapy 7:1.
Crossref
Shengli Xia, Kai Duan, Yuntao Zhang, Xiaoqing Zeng, Dongyang Zhao, Huajun Zhang, Zhiqiang Xie, Xinguo Li, Cheng Peng, Wei Zhang, Yunkai Yang, Wei Chen, Xiaoxiao Gao, Wangyang You, Xuewei Wang, Zejun Wang, Zhengli Shi, Yanxia Wang, Xuqin Yang, Qingliang Li, Lili Huang, Qian Wang, Jia Lu, Yongli Yang, Jing Guo, Wei Zhou, Xin Wan, Cong Wu, Wenhui Wang, Shihe Huang, Jianhui Du, Xuanxuan Nian, Tao Deng, Zhiming Yuan, Shuo Shen, Wanshen Guo, Jia Liu & Xiaoming Yang. (2022) Safety and Immunogenicity of an Inactivated COVID-19 Vaccine, WIBP-CorV, in Healthy Children: Interim Analysis of a Randomized, Double-Blind, Controlled, Phase 1/2 Trial. Frontiers in Immunology 13.
Crossref
Chao Wang, Lin-Yi Chen, Qing-Bin Lu & Fuqiang Cui. (2022) Vaccination with the Inactivated Vaccine (Sinopharm BBIBP-CorV) Ensures Protection against SARS-CoV-2 Related Disease. Vaccines 10:6, pages 920.
Crossref
Nawal Al Kaabi, Yun Kai Yang, Jing Zhang, Ke Xu, Yu Liang, Yun Kang, Ji Guo Su, Tian Yang, Salah Hussein, Mohamed Saif ElDein, Shuai Shao, Sen Sen Yang, Wenwen Lei, Xue Jun Gao, Zhiwei Jiang, Hui Wang, Meng Li, Hanadi Mekki Mekki, Walid Zaher, Sally Mahmoud, Xue Zhang, Chang Qu, Dan Ying Liu, Jing Zhang, Mengjie Yang, Islam Eltantawy, Peng Xiao, Zhao Nian Wang, Jin Liang Yin, Xiao Yan Mao, Jin Zhang, Ning Liu, Fu Jie Shen, Liang Qu, Yun Tao Zhang, Xiao Ming Yang, Guizhen Wu & Qi Ming Li. (2022) Immunogenicity and safety of NVSI-06-07 as a heterologous booster after priming with BBIBP-CorV: a phase 2 trial. Signal Transduction and Targeted Therapy 7:1.
Crossref
Evropi Amanatidou, Anna Gkiouliava, Eva Pella, Maria Serafidi, Dimitrios Tsilingiris, Natalia G. Vallianou, Ιrene Karampela & Maria Dalamaga. (2022) Breakthrough infections after COVID-19 vaccination: Insights, perspectives and challenges. Metabolism Open 14, pages 100180.
Crossref
Javeria Aijaz, Shakir Hussain, Fouzia Naseer, Fatima Kanani, Sabiha Anis, Samreen Sarfaraz, Saima Saeed, Hina Farooq & Saba Jamal. (2022) Neutralizing Antibody Response to BBIBP-CorV in Comparison with COVID-19 Recovered, Unvaccinated Individuals in a Sample of the Pakistani Population. Vaccines 10:5, pages 692.
Crossref
Yao Fan, Xiang Li, Lei Zhang, Shu Wan, Long Zhang & Fangfang Zhou. (2022) SARS-CoV-2 Omicron variant: recent progress and future perspectives. Signal Transduction and Targeted Therapy 7:1.
Crossref
Qianyu Duan, Shuai Xia, Fanke Jiao, Qian Wang, Rui Wang, Lu Lu, Shibo Jiang & Wei Xu. (2022) A Modified Fibronectin Type III Domain-Conjugated, Long-Acting Pan-Coronavirus Fusion Inhibitor with Extended Half-Life. Viruses 14:4, pages 655.
Crossref
Naru Zhang, Qianting Ji, Zezhong Liu, Kaiming Tang, Yubin Xie, Kangchen Li, Jie Zhou, Sisi Li, Haotian Shang, Zecan Shi, Tianyu Zheng, Jiawei Yao, Lu Lu, Shuofeng Yuan & Shibo Jiang. (2022) Effect of Different Adjuvants on Immune Responses Elicited by Protein-Based Subunit Vaccines against SARS-CoV-2 and Its Delta Variant. Viruses 14:3, pages 501.
Crossref